Oslo - Delayed Quote NOK

Gentian Diagnostics ASA (GENT.OL)

55.00
-2.00
(-3.51%)
At close: May 9 at 4:26:50 PM GMT+2
Loading Chart for GENT.OL
  • Previous Close 57.00
  • Open 58.00
  • Bid 58.00 x --
  • Ask 58.40 x --
  • Day's Range 57.00 - 61.80
  • 52 Week Range 36.60 - 61.80
  • Volume 61,702
  • Avg. Volume 9,228
  • Market Cap (intraday) 848.232M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 17.80
  • EPS (TTM) 3.09
  • Earnings Date --
  • Forward Dividend & Yield 0.40 (0.73%)
  • Ex-Dividend Date May 7, 2025
  • 1y Target Est 67.00

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also develops NT-proBNP Immunoassay, an aid in the diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure, which is in product development phase. In addition, the company provides faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

www.gentian.com

63

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GENT.OL

View More

Performance Overview: GENT.OL

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .

YTD Return

GENT.OL
41.45%
OBX Total Return Index (OBX.OL)
6.94%

1-Year Return

GENT.OL
43.65%
OBX Total Return Index (OBX.OL)
8.87%

3-Year Return

GENT.OL
26.02%
OBX Total Return Index (OBX.OL)
32.99%

5-Year Return

GENT.OL
6.63%
OBX Total Return Index (OBX.OL)
104.42%

Compare To: GENT.OL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GENT.OL

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    848.23M

  • Enterprise Value

    763.83M

  • Trailing P/E

    17.80

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.51

  • Price/Book (mrq)

    4.17

  • Enterprise Value/Revenue

    5.09

  • Enterprise Value/EBITDA

    26.06

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    30.93%

  • Return on Assets (ttm)

    7.35%

  • Return on Equity (ttm)

    27.55%

  • Revenue (ttm)

    158.07M

  • Net Income Avi to Common (ttm)

    48.89M

  • Diluted EPS (ttm)

    3.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    88.74M

  • Total Debt/Equity (mrq)

    2.14%

  • Levered Free Cash Flow (ttm)

    -5.34M

Research Analysis: GENT.OL

View More

Company Insights: GENT.OL

Research Reports: GENT.OL

View More

People Also Watch